Brainstorm Cell Therapeutics (STU:GHD) Inventories, Raw Materials & Components: €0.00 Mil (As of Mar. 2026)


STU:GHD Brainstorm Cell Therapeutics Inc STU:GHD
28 GF Score
Price €2.98
! 3 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Inventories, Raw Materials & Components?

Brainstorm Cell Therapeutics STU:GHD 28 Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:GHD with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Brainstorm Cell Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €0.00 Mil.

Brainstorm Cell Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics Inventories, Raw Materials & Components Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Brainstorm Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:GHD
28GF Score
Brainstorm Cell Therapeutics Inc STU:GHD
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
Brainstorm Cell Therapeutics (STU:GHD) has a Inventories, Raw Materials & Components of €0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Brainstorm Cell Therapeutics and its competitors.
Is Brainstorm Cell Therapeutics' Inventories, Raw Materials & Components too high?
Brainstorm Cell Therapeutics' current Inventories, Raw Materials & Components is €0.00 Mil. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' Inventories, Raw Materials & Components compare to ADAPY and APRE?
Brainstorm Cell Therapeutics' Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current Inventories, Raw Materials & Components of €0.00 Mil. The current Inventories, Raw Materials & Components is €0.00 Mil. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Other Exchanges BCLI:USA
Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for STU:GHD

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price